Puma Biotechnology, Inc.
NASDAQ:PBYIBiotechnology
+$0.16 today
- Market cap
- $373.26M
- Beta
- 1.21
- P/E (TTM)
- 15.4
- EPS (TTM)
- $0.48
Volume 0.45M
Average 0.26M
PBYI Operating Cash Flow
Cash generated by the company's core business operations during the period.
Puma Biotechnology, Inc.NASDAQ: PBYI
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $15.42M rose 326.8% year over year, ahead of the +71.4% change in trailing-twelve-month operating cash flow. Sequentially, it rose 6.9% from the prior quarter.
Context
- Operating cash flow amounted to 18.3% of revenue in FY2025, up 1.4 pp from a year earlier.
- Operating cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +326.8% holds above the trailing-twelve-month pace of +71.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 41.8M USD
- Year-over-year change
- +7.4%
- 4-year CAGR
- +19.3%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.8M | +7.4% |
| FY2024 | 2024-12-31 | 38.92M | +44.1% |
| FY2023 | 2023-12-31 | 27.01M | +270.7% |
| FY2022 | 2022-12-31 | (15.83M) | -176.6% |
| FY2021 | 2021-12-31 | 20.65M | — |
Operating Cash Flow vs competitors
How PBYI compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +71.4% is the highest of 10, against a peer median of +0.5%.
- Operating cash flow amounts to 23.6% of revenue for PBYI, versus a peer median of 176.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $150.95M USD | +31.1% | +29.3% | 304.4% | |
| LTM Sep 2026 | $150.09M USD | +2.9% | +8.4% | — | |
| LTM Mar 2026 | $134.47M USD | +12.4% | +54.4% | — | |
| LTM Mar 2026 | $110.88M USD | -3.8% | +14.7% | — | |
| LTM Jun 2026 | $82.62M USD | -50.9% | +21.7% | 48.6% | |
| LTM Mar 2026 | $69.96M USD | +0.5% | -2.3% | 44.5% | |
| LTM Mar 2026 | $53.61M USD | +71.4% | — | 23.6% | |
| LTM Mar 2026 | $37.42M USD | -12.5% | +3.9% | 7127.0% | |
| LTM Mar 2026 | $34.03M USD | -376.5% | — | — | |
| LTM Mar 2026 | CA$30.89M CAD | +18.8% | +5.7% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.15M CNY | — | -73.5% | — |
| Peer median (excluding PBYI) | — | +0.5% | +8.4% | 176.5% | |
Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (29.13M) | 2K | 21.59M | 30.28M | 31.11M |
| Depreciation & Amortization | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| Deferred Income Tax | 0 | 0 | 0 | (7.08M) | 3.25M |
| Stock-Based Compensation | 32.63M | 11.83M | 10.25M | 8.25M | 6.94M |
| Change in Working Capital | (1.31M) | (44.5M) | (17.85M) | (3.54M) | (10.08M) |
| Accounts Receivables | (5.98M) | (7.82M) | (8.37M) | 16.35M | (21.28M) |
| Inventory | (3.66M) | 2.58M | (2.55M) | (1.64M) | 3.21M |
| Accounts Payables | (902K) | (4.73M) | 449K | (1.38M) | (453K) |
| Other Working Capital | 9.23M | (34.52M) | (7.38M) | (16.86M) | 8.45M |
| Other Non-Cash Items | 7.15M | 7M | 1.51M | (519K) | (358K) |
| Operating Cash Flow | 20.65M | (15.83M) | 27.01M | 38.92M | 41.8M |
| Capital Expenditures | 0 | (7M) | (12.64M) | (56K) | (71K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (38.07M) | (4.84M) | (23.81M) | (76.23M) | (108.14M) |
| Sales of Investments | 27.19M | 18.94M | 17.33M | 55.85M | 72.02M |
| Other Investing Activities | 0 | 0 | (12.5M) | 0 | 0 |
| Investing Cash Flow | (10.88M) | 7.1M | (19.13M) | (20.44M) | (36.19M) |
| Debt Repayment | (1.5M) | 0 | 0 | (33.33M) | (44.44M) |
| Common Stock Issued | 0 | 12.5M | 0 | 150K | 130K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (30.43M) | (277K) | 0 | (666K) | (888K) |
| Financing Cash Flow | (31.93M) | 12.22M | 0 | (33.85M) | (45.2M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (22.16M) | 3.5M | 7.88M | (15.37M) | (39.58M) |
| Free Cash Flow | 20.65M | (22.83M) | 14.37M | 38.86M | 41.73M |
Puma Biotechnology, Inc.
NASDAQ:PBYI
Intrinsic Alpha fair value
Locked
Current Price
$7.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.